Qube Research & Technologies (QRT)
CRVS icon

Qube Research & Technologies (QRT)’s Corvus Pharmaceuticals CRVS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$486K Sell
33,228
-81,272
-71% -$1.3M ﹤0.01% 2744
2025
Q4 		$882K Buy
+114,500
New +$903K ﹤0.01% 2602
2025
Q3 		– Sell
-43,969
Closed -$176K – 3635
2025
Q2 		$176K Sell
43,969
-405,111
-90% -$1.47M ﹤0.01% 2936
2025
Q1 		$1.43M Sell
449,080
-970
-0.2% -$4.57K ﹤0.01% 2107
2024
Q4 		$2.41M Buy
450,050
+322,718
+253% +$2.41M ﹤0.01% 1805
2024
Q3 		$672K Buy
+127,332
New +$457K ﹤0.01% 2175
2024
Q2 		– Sell
-2,378
Closed -$4.23K – 3943
2024
Q1 		$4.23K Buy
+2,378
New +$4.97K ﹤0.01% 3914
2020
Q4 		– Sell
-61,724
Closed -$248K – 1869
2020
Q3 		$248K Buy
61,724
+50,083
+430% +$200K ﹤0.01% 1318
2020
Q2 		$32K Buy
+11,641
New +$34.4K ﹤0.01% 1642

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CRVS Position: Q1 2026 in Review

Qube Research & Technologies (QRT) reduced its Corvus Pharmaceuticals (CRVS) stake by 71% in Q1 2026, selling an estimated $1.3M and leaving 33,228 shares worth $486K. The position accounts for ﹤0.01% of the portfolio, ranked #2744.

Qube Research & Technologies (QRT) first reported a position in CRVS in Q2 2020 and has held it in 9 quarters since. The position peaked at $2.41M in Q4 2024. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Qube Research & Technologies (QRT) held 33,228 shares of Corvus Pharmaceuticals worth $486K as of Q1 2026.
  • Qube Research & Technologies (QRT) sold 81,272 Corvus Pharmaceuticals shares in Q1 2026, an estimated $1.3M.
  • Corvus Pharmaceuticals made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #2744 holding.
  • Qube Research & Technologies (QRT) first reported a position in Corvus Pharmaceuticals in Q2 2020 and has held it in 9 quarters since.
  • Qube Research & Technologies (QRT)'s Corvus Pharmaceuticals position peaked at $2.41M in Q4 2024.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.